Technology | July 30, 2014

Covidien Launches Next-Generation Trellis Peripheral Infusion System

Treatment for DVT redesigned to improve thrombus isolation, lytic drug delivery, removal of blood clot


July 30, 2014 — Covidien announced the commercial launch of its next-generation Trellis peripheral infusion system. The redesigned system continues to be the only pharmacomechanical thrombolysis device that enables focused treatment of blood clots that lead to post-thrombotic syndrome (PTS). This latest Trellis system has been optimized to enhance drug delivery and the removal of the dissolved clot.

PTS is a long-term effect of deep vein thrombosis (DVT), a condition where a clot develops in one of the body’s deep veins above the knee. PTS develops when a DVT interferes with the blood flow returning from the leg back to the heart. It can cause lower leg pain and swelling, and can damage the valves in the veins that normally stop blood from flowing backwards down the leg. PTS occurs in almost half of patients within two years after DVT, and up to 33 percent of patients with PTS develop ulcers and skin deterioration.

The Trellis system provides a way for physicians to dissolve acute thrombus and intervene on DVT before it advances to PTS. The system is comprised of an over-the-wire catheter with two occlusive balloons to close off the treatment area and block drug release to other areas of the body; an infusion zone to deliver the lytic drug; and an oscillation drive unit that disperses the drug to dissolve the clot. The updated Trellis system features enhanced drug delivery and increased amplitude of the dispersion wire to better distribute the drug throughout the clot. Additionally, the new system features a larger aspiration window than the previous version, which allows for better removal of the drug and the dissolved clot.

“Covidien is committed to providing clinicians and patients with advanced technology that is clinically relevant and demonstrates economic value. Our clinical data has demonstrated that the Trellis system’s targeted lytic delivery may reduce the risk of bleeding complications normally associated with systemic thrombolytic infusion,” said Mark A. Turco, M.D., chief medical officer, vascular therapies, Covidien. “Furthermore, intervening in patients with DVT may help improve long-term outcomes in a population that can suffer significant complications if left untreated.”

The Trellis peripheral infusion system is currently available in the United States, Europe and Canada.

For more information: www.covidien.com


Related Content

News | Catheters

December 5, 2022 — The U.S. Food and Drug Administration (FDA) is alerting health care facilities and providers of a ...

Home December 05, 2022
Home
Feature | Catheters | By Allied Market Research

According to a new report from Allied Market Research, the global catheters market was valued at $22.7 billion in 2021 ...

Home June 09, 2022
Home
News | Catheters

May 10, 2022 — The MIVI Neuroscience Q Aspiration Catheter incorporates a novel pusher wire design on its proximal end ...

Home May 10, 2022
Home
News | Catheters
April 21, 2022 – MIVI Neuroscience, Inc., innovator of the next generation of neurointerventional medical devices, today ...
Home April 21, 2022
Home
News | Catheters

February 9, 2022 — Innovative Health, LLC, a specialty cardiology reprocessor, has announced that the company has ...

Home February 09, 2022
Home
News | Catheters

October 23, 2019 — BioCardia announced the U.S. commercial availability of its Avance Bi-Directional Steerable ...

Home October 23, 2019
Home
Technology | Catheters

August 23, 2019 — Cook Medical recently released the second generation of the 2.6 Fr CXI Support Catheter with platinum ...

Home August 23, 2019
Home
Technology | Catheters

May 16, 2019 — BioCardia Inc. announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the Avance steerable ...

Home May 16, 2019
Home
News | Catheters

February 21, 2019 — Navitian, the new coronary microcatheter from iVascular, recently received CE mark approval. The ...

Home February 21, 2019
Home
Subscribe Now